ARTICLE | Clinical News

BL-8040: Phase I started

September 15, 2014 7:00 AM UTC

BioLineRx began a 2-part, Israeli Phase I trial of subcutaneous BL-8040 in up to 40 healthy male volunteers. In a double-blind, placebo-controlled, dose-escalation part, up to 32 volunteers will receive BL-8040 once daily on 2 consecutive days. The open-label second part will further evaluate the dose selected from the first part given once daily for 1 or 2 days in 8 volunteers. ...